Evidence map›Paper›PMID 35921992›Full record

ArticleActa biomaterialia2022

Tissue-adhesive hydrogel for multimodal drug release to immune cells in skin.

Nicole B Day, Rianne Dalhuisen, Nichole E Loomis, Sarah G Adzema, Jai Prakash, C Wyatt Shields Iv

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Acta biomaterialia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Hydrogel applications: a promising frontier in pneumonia therapy.Frontiers in bioengineering and biotechnology · 2025
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Nicole B DayDepartment of Chemical and Biological Engineering, University of Colorado Boulder, Boulder CO 80303, United States.
Rianne DalhuisenDepartment of Chemical and Biological Engineering, University of Colorado Boulder, Boulder CO 80303, United States; Department of Advanced Organ Bioengineering and Therapeutics, Section: Engineered Therapeutics, University of Twente, Enschede, the Netherlands.
Nichole E LoomisDepartment of Chemical and Biological Engineering, University of Colorado Boulder, Boulder CO 80303, United States.
Sarah G AdzemaDepartment of Chemical and Biological Engineering, University of Colorado Boulder, Boulder CO 80303, United States.
Jai PrakashDepartment of Advanced Organ Bioengineering and Therapeutics, Section: Engineered Therapeutics, University of Twente, Enschede, the Netherlands.
C Wyatt Shields IvDepartment of Chemical and Biological Engineering, University of Colorado Boulder, Boulder CO 80303, United States; Biomedical Engineering Program, University of Colorado Boulder, Boulder CO 80303, United States. Electronic address: Charles.Shields@colorado.edu.
University of Colorado Boulder · USUniversity of Twente · NL

Funding

Predoctoral Training Molecular BiophysicsT32GM065103 · NIGMS · UNIVERSITY OF COLORADO AT BOULDER · PI FALKE, JOSEPH J · 2002 to 2021
$4.3M
Mechanisms of p27Kipl Proteolysis in Cancer CellsR01CA107098 · NCI · UNIVERSITY OF COLORADO AT BOULDER · PI LIU, XUEDONG · 2004 to 2012
$2.7M
Interdisciplinary Predoctoral Training in Molecular BiophysicsT32GM145437 · NIGMS · UNIVERSITY OF COLORADO · PI JOSEPH J FALKE · 2022 to 2026
$2.5M
FACSAria Fusion Cell SorterS10OD021601 · OD · UNIVERSITY OF COLORADO · PI LIU, XUEDONG · 2016 to 2016
$599k
NCI NIH HHS R01 CA107098NIGMS NIH HHS T32 GM065103NIGMS NIH HHS T32 GM145437NIH HHS S10 OD021601
6 · The paper itself

Abstract

Both innate and adaptive immune systems play a crucial role in the pathology of skin diseases. To control these cells, there is a need for transdermal drug delivery systems that can target multiple cell populations at independently tunable rates. Herein, we describe a tissue-adhesive hydrogel system that contains particles capable of regulating the release of small molecule drugs at defined rates. Resiquimod (a macrophage-targeting drug) and palbociclib (a T cell-targeting drug) are encapsulated within two types of silicone particles embedded within the hydrogel. We demonstrate that drug release is mediated by the crosslink density of the particles, which is decoupled from the bulk properties of the hydrogel. We show that this system can be used to sustainably polarize macrophages toward an anti-tumor phenotype in vitro and ex vivo, and that the hydrogels can remain attached to skin explants for several days without generating toxicity. The hydrogel system is compatible with standard dermatological procedures and allows transdermal passage of drugs. The multimodal, tunable nature of this system has implications in treating a variety of skin disorders, managing infections, and delivering vaccines. STATEMENT OF SIGNIFICANCE: We describe a tissue-adhesive hydrogel that can regulate the release of drugs in a manner that is decoupled from its bulk properties. The mechanism of drug release is mediated by embedded microparticles with well-defined crosslink densities. The significance of this system is that, by encapsulating different drugs into the particles, it is possible to achieve multimodal drug release. We demonstrate this capability by releasing two immunomodulatory drugs at disparate rates. A drug that targets innate immune cells is released quickly, and a drug that targets adaptive immune cells is released slowly. This programmable system offers a direct means by which cellular responses can be enhanced through independent targeting for a variety of transdermal applications, including cancer treatment and vaccine delivery.

Indexed as

HydrogelsTissue AdhesivesAdministration, CutaneousDrug Delivery SystemsDrug LiberationHydrogelsTissue AdhesivesDrug deliveryHydrogelImmunotherapyMacrophage polarizationMicroparticles

Identifiers

PMID35921992
PMCPMC12217073
OpenAlexW4289172239

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.